Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada
- PMID: 21498152
- DOI: 10.1310/hct1202-89
Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada
Abstract
Purpose: This study assessed ethnicity and gender differences in prevalence, type, and severity of antiretroviral-associated lipodystrophy in HIV-positive individuals in Ontario.
Methods: This was a cross-sectional analysis of the Ontario Cohort Study (OCS), a prospective study of HIV-positive patients in Ontario. Lipodystrophy was defined as at least 1 major or 2 minor self-reported changes of peripheral lipoatrophy and/or central lipohypertrophy. Prevalence, type, and severity were compared by ethnicity (Black, White, or Other) and gender. Univariate and multivariate logistic regression analyses identified predictors of lipodystrophy.
Results: Data were available for 778 participants (659 men, 119 women). There were 517 Whites, 121 Blacks, and 140 patients of Other ethnicities. In univariate analyses, Whites reported more peripheral lipoatrophy (P = .004) and abdominal lipohypertrophy (P = .04); these ethnic differences were observed in males (P = .05 and P = .03, respectively) but not females. Males reported more peripheral lipoatrophy (P = .01), whereas females had more central lipohypertrophy (P < .0001) and mixed fat redistribution (P < .0001). Multivariable regression analyses revealed Black women to be most vulnerable to lipodystrophy (P = .02), particularly lipohypertrophy (P < .0001).
Conclusions: Ethnicity and gender are important factors influencing lipodystrophy. Combining lipoatrophy and lipohypertrophy into a single entity is not appropriate. Black women were most vulnerable to lipohypertrophy, which has important implications for antiretroviral therapy roll-out in Africa.
Similar articles
-
HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.HIV Med. 2003 Jul;4(3):293-301. doi: 10.1046/j.1468-1293.2003.00159.x. HIV Med. 2003. PMID: 12859330
-
Discordance between body mass index and anthropometric measurements among HIV-1-infected patients on antiretroviral therapy and with lipoatrophy/lipohypertrophy syndrome.Rev Inst Med Trop Sao Paulo. 2015 Mar-Apr;57(2):105-10. doi: 10.1590/S0036-46652015000200002. Rev Inst Med Trop Sao Paulo. 2015. PMID: 25923888 Free PMC article.
-
Adipocytokine dysregulation, abnormal glucose metabolism, and lipodystrophy in HIV-infected adolescents receiving protease inhibitors.Cytokine. 2020 Dec;136:155145. doi: 10.1016/j.cyto.2020.155145. Epub 2020 Sep 10. Cytokine. 2020. PMID: 32920318 Clinical Trial.
-
HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings.J Int AIDS Soc. 2015 Jan 15;18(1):19033. doi: 10.7448/IAS.18.1.19033. eCollection 2015. J Int AIDS Soc. 2015. PMID: 25598476 Free PMC article. Review.
-
What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection.Curr Opin Infect Dis. 2004 Feb;17(1):27-32. doi: 10.1097/00001432-200402000-00005. Curr Opin Infect Dis. 2004. PMID: 15090886 Review.
Cited by
-
Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases.Bioessays. 2012 Dec;34(12):1050-9. doi: 10.1002/bies.201200099. Epub 2012 Sep 26. Bioessays. 2012. PMID: 23012250 Free PMC article.
-
Lipodystrophy among HIV-Infected Patients Attending Care and Treatment Clinics in Dar es Salaam.AIDS Res Treat. 2017;2017:3896539. doi: 10.1155/2017/3896539. Epub 2017 Oct 11. AIDS Res Treat. 2017. PMID: 29158917 Free PMC article.
-
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.AIDS Patient Care STDS. 2012 Sep;26(9):532-40. doi: 10.1089/apc.2012.0135. Epub 2012 Jul 23. AIDS Patient Care STDS. 2012. PMID: 22823027 Free PMC article. Clinical Trial.
-
Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race.Open Forum Infect Dis. 2018 Nov 16;5(11):ofy201. doi: 10.1093/ofid/ofy201. eCollection 2018 Nov. Open Forum Infect Dis. 2018. PMID: 30465010 Free PMC article.
-
Viral mechanisms of adipose dysfunction: lessons from HIV-1 Vpr.Adipocyte. 2014 Oct 30;4(1):55-9. doi: 10.4161/adip.29852. eCollection 2015 Jan-Mar. Adipocyte. 2014. PMID: 26167403 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical